[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cedar Valley Digestive Health Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100551434",false,"NCT06460038","Tenapanor in Synucleinopathy-Related Constipation","Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation","Inclusion Criteria\n\n1. Age 50-89 years.\n2. Diagnosis of PD within Hoehn and Yahr stages 1-3, confirmed by a neurologist per International Parkinson and Movement Disorder Society criteria.\n3. Average weekly stool frequency of ≤5 spontaneous bowel movements (SBMs) and ≤2 complete spontaneous bowel movements (CSBMs) over the past 6 months. These criteria will be verified during a 2-week screening period.\n4. Stool consistency ≤3 on the Bristol Stool Form Scale (BSFS). This criterion will be verified during a 2-week screening period.\n5. Agreement to use contraception, if applicable.\n\nExclusion Criteria\n\n1. Functional diarrhea or IBS-D\u002FM based on Rome IV Criteria.\n2. Symptomatic structural GI abnormalities or inflammatory bowel disease.\n3. Significant hepatic (ALT or AST ≥ 2.5x the upper limit of normal) or renal (serum creatinine \\>2mg\u002Fdl) dysfunction.\n4. Pregnancy or lactation.\n5. Diagnosis of primary dyssynergic defecation by anorectal manometry.","ALL","50 Years","89 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation",[26,27],"Synucleinopathy","Parkinson's Disease",[29,30,31,32],"tenapanor","synucleinopathy","Parkinson's disease","constipation","RECRUITING","2025-02-06",{"date":36,"type":37},"2025-02-10","ACTUAL",{"date":39,"type":37},"2025-01-01",{"date":41,"type":20},"2027-03",{"name":43,"class":44},"Cedar Valley Digestive Health Center","OTHER",""]